Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. NATIONAL STOCK EXCHANGE OF AUSTRALIA LIMITED
  5. IQX Limited
  6. News
  7. Summary
    IQX   AU000000IQX4

IQX LIMITED

(IQX)
End-of-day quote. End-of-day quote NATIONAL STOCK EXCHANGE OF AUSTRALIA LIMITED - 08/10
0.13 AUD   +85.71%
10/18IQX : Filed a Pre-Submission package with the United States (US) Food and Drug Administration (FDA).
PU
09/09IQX : Annual Report June 2021
PU
09/09IQX Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

IQX Limited (NSX:IQX) Portfolio Company Awarded $6.3M Federal Govt Grant

07/08/2021 | 08:03pm EDT

Sydney, Australia, July 9, 2021 - (ABN Newswire) - iQX Limited (NSX:IQX), on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), in which IQX holds 19% equity position, that LSBD's subsidiary GBS today announced it has been awarded a AUD $6.3 million, Australian Federal Government scientific grant to create a pilot Biosensor manufacturing facility. GBS Inc (NAS:GBS) is a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care. This project has been identified as one of six National Manufacturing Priorities identified by the Government under Modern Manufacturing Strategy (MMS).

The Medical Products Priority Grant, from the Australian Federal Government's Department of Industry, Science, Energy and Resources' Modern Manufacturing Initiative will support the establishment of an Australian high tech medical device manufacturing facility to commence scaled production of the Printable Organic Electronic Biosensor technology for the APAC region.

GBS's flagship product, the Saliva Glucose Biosensor (SGB), is the first innovation to be developed from the Biosensor Platform and is currently being developed as a point-of-care test intended to provide people living with diabetes a non-invasive solution to finger-prick blood glucose testing. This alternative test will offer a pain-free option to current testing methods by using an Organic Thin-Film Transistor (OTFT) that produces glucose measurements in real-time on an app or dedicated device for the more than 460 million people living with diabetes worldwide.

Supplementary to the SGB, GBS also plans to commercialise a SARS-CoV-2 Antibody Biosensor, a rapid point-of-care diagnostic test to monitor exposure and immunity levels in real time in the fight against COVID-19. The SARS-CoV-2 Biosensor is being developed in collaboration with the Wyss Institute for Biologically Inspired Engineering at Harvard University. The Biosensor will be integrated with the Institute's eRapid electrochemical sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection for point-of-care COVID-19 diagnostic applications.

The eRapid technology was developed by a cross-disciplinary team led by Wyss Founding Director Donald Ingber, M.D., Ph.D. and Wyss Senior Staff Scientist Pawan Jolly, Ph.D. as a low-cost, affinity-based electrochemical sensing platform that can simultaneously detect and quantify a broad range of biomarkers, with high sensitivity and selectivity, from a small volume of saliva or blood.

GBS's manufacturing facility will have capacity to produce an annual supply of 100M biosensor units for roll-out to primary global commercialisation sites in the Asia Pacific (APAC) region.

The need to commence scaled production of the SGB and SARS-CoV-2 Antibody Biosensor follows rigorous testing and research of the technology supported by Harvard University and the Johns Hopkins Environmental Health Microbiology and Immunology Laboratory at the Johns Hopkins Bloomberg School of Public Health, and the lab's Salivary Biomarkers and Infectious Diseases Program.

Following the successful commercialisation of the SGB, the biosensor technology will be applied to additional point-of-care applications, including diagnosis/management of cancer, infectious disease, and allergies. In total, there are currently 130 indications under development, all of which seek to enable healthier communities globally.

GBS's technology is an Australian invention, resulting from 20 years of research and development by Professor Paul Dastoor and his team at the University of Newcastle's Centre for Organic Electronics. Prof Dastoor is a global leader in the emerging field of Organic Electronics Sensor Printing, which uses conventional roll-to-roll printing technology to produce low-cost medical diagnostics.

"Our entire business model is all about translation of discovery into a product that fills an unmet medical need, creating a dedicated high tech manufacturing facility to commence production for our Glucose Biosensor will benefit the local society by creating jobs, but most importantly the patients afflicted with diabetes and up till now had to finger prick multiple times a day in order to monitor their glucose levels. This grant could not have come at a more appropriate time, since we are preparing for clinical testing." Group Chief Executive Officer of The iQ Group Global, Dr. George Syrmalis said.

GBS Chief Executive Officer Harry Simeonidis added, "We are pleased with this significant grant as it allows us not only to further advance our technology but also continue to develop future point-of-care diagnostics test. The new high-tech medical device facility will support local jobs in Australia and allow GBS to manufacture medical diagnostics test for Australia and Asia."


<b>About IQX Limited:</b>

A member of The iQ Group Global, iQX Limited is an investment funds management company specialising in the bioscience sector that is committed to eradicating disease through capital investment.

Copyright (C) 2021 ABN Newswire. All rights reserved., source Press Releases English

Stocks mentioned in the article
ChangeLast1st jan.
GBS INC. 2.68% 2.3 Delayed Quote.-68.92%
IQX LIMITED 85.71% 0.13 End-of-day quote.0.00%
THE IQ GROUP GLOBAL LTD. 0.00% 0.2 End-of-day quote.-55.56%
All news about IQX LIMITED
10/18IQX : Filed a Pre-Submission package with the United States (US) Food and Drug Administrat..
PU
09/09IQX : Annual Report June 2021
PU
09/09IQX Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
07/08IQX LIMITED (NSX : IQX) Portfolio Company Awarded $6.3M Federal Govt Grant
AQ
04/29IQX LIMITED (NSX : IQX) Progress of Clinical Programs
AQ
03/09Iqx Limited Reports Earnings Results for the Half Year Ended December 31, 2020
CI
2020Iqx Limited Reports Earnings Results for the Full Year Ended June 30, 2020
CI
2020Iqx Limited Reports Earnings Results for the Half Year Ended December 31, 2019
CI
2019Iqx Limited Reports Earnings Results for the Full Year Ended June 30, 2019
CI
2019IQX Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, ..
CI
More news
Financials
Sales 2021 3,83 M 2,88 M 2,88 M
Net income 2021 -23,1 M -17,4 M -17,4 M
Net Debt 2021 5,98 M 4,50 M 4,50 M
P/E ratio 2021 -1,31x
Yield 2021 -
Capitalization 56,2 M 42,2 M 42,3 M
EV / Sales 2020 13,5x
EV / Sales 2021 9,45x
Nbr of Employees -
Free-Float -
Chart IQX LIMITED
Duration : Period :
iQX Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
George Syrmalis Chief Executive Officer & Executive Director
Kosmas Dimitriou Chairman
John Stratilas Independent Non-Executive Director
Peter Buchanan Simpson Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
IQX LIMITED0.00%42
MODERNA, INC.218.76%134 660
LONZA GROUP AG27.07%58 240
IQVIA HOLDINGS INC.40.38%47 715
SEAGEN INC.-0.17%31 691
CELLTRION, INC.-39.00%25 332